TAS‐116 (pimitespib), a heat shock protein 90 inhibitor, shows efficacy in preclinical models of adult T‐cell leukemia
暂无分享,去创建一个
K. Yanagihara | D. Sasaki | H. Hasegawa | Y. Miyazaki | I. Hamaguchi | K. Morishita | Y. Tsukamoto | Y. Imaizumi | E. Ikebe | Yu Wang | H. Iha | Shunsuke Shimosaki
[1] T. Tsukiyama,et al. HTLV-1 targets human placental trophoblasts in seropositive pregnant women. , 2020, The Journal of clinical investigation.
[2] K. Tsukasaki,et al. Novel Treatments of Adult T Cell Leukemia Lymphoma , 2020, Frontiers in Microbiology.
[3] B. Blagg,et al. Old and New Approaches to Target the Hsp90 Chaperone. , 2019, Current cancer drug targets.
[4] J. Nakashima,et al. Treatment with mogamulizumab or lenalidomide for relapsed adult T‐cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: The Nagasaki transplant group experience , 2019, Hematological oncology.
[5] K. T. Chong,et al. Discovery of 3-Ethyl-4-(3-isopropyl-4-(4-(1-methyl-1 H-pyrazol-4-yl)-1 H-imidazol-1-yl)-1 H-pyrazolo[3,4- b]pyridin-1-yl)benzamide (TAS-116) as a Potent, Selective, and Orally Available HSP90 Inhibitor. , 2018, Journal of medicinal chemistry.
[6] B. Barbeau,et al. Hijacking of the AP-1 Signaling Pathway during Development of ATL , 2018, Front. Microbiol..
[7] Elisa Cirillo,et al. A Review of Pathway-Based Analysis Tools That Visualize Genetic Variants , 2017, Front. Genet..
[8] M. Ogura,et al. Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma: ATLL-002. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] J. Bendell,et al. A Phase 2 Study of the Hsp90 Inhibitor AUY922 as Treatment for Patients with Refractory Gastrointestinal Stromal Tumors , 2016, Cancer investigation.
[10] H. Aburatani,et al. Integrated molecular analysis of adult T cell leukemia/lymphoma , 2015, Nature Genetics.
[11] S. Ohkubo,et al. TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90α and β, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models , 2014, Molecular Cancer Therapeutics.
[12] K. Tsukasaki,et al. Heat shock protein 90 inhibitor NVP-AUY922 exerts potent activity against adult T-cell leukemia–lymphoma cells , 2014, Cancer science.
[13] M. McKeown,et al. Therapeutic strategies to inhibit MYC. , 2014, Cold Spring Harbor perspectives in medicine.
[14] K. Ishitsuka,et al. Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma. , 2014, The Lancet. Oncology.
[15] R. Bates,et al. A rat retinal damage model predicts for potential clinical visual disturbances induced by Hsp90 inhibitors. , 2013, Toxicology and applied pharmacology.
[16] E. Harhaj,et al. HSP90 Protects the Human T-Cell Leukemia Virus Type 1 (HTLV-1) Tax Oncoprotein from Proteasomal Degradation To Support NF-κB Activation and HTLV-1 Replication , 2013, Journal of Virology.
[17] M. Dimopoulos,et al. Hsp90 inhibitors in breast cancer: a systematic review. , 2013, Breast.
[18] K. Jeang,et al. Oral administration of an HSP90 inhibitor, 17-DMAG, intervenes tumor-cell infiltration into multiple organs and improves survival period for ATL model mice , 2013, Blood Cancer Journal.
[19] Y. Miyata,et al. The therapeutic target Hsp90 and cancer hallmarks. , 2012, Current pharmaceutical design.
[20] A. Gessain,et al. Epidemiological Aspects and World Distribution of HTLV-1 Infection , 2012, Front. Microbio..
[21] K. Yamaguchi,et al. Adult T-Cell Leukemia: A Review of Epidemiological Evidence , 2012, Front. Microbio..
[22] Chi V Dang,et al. MYC on the Path to Cancer , 2012, Cell.
[23] Makoto Yamagishi,et al. Polycomb-mediated loss of miR-31 activates NIK-dependent NF-κB pathway in adult T cell leukemia and other cancers. , 2012, Cancer cell.
[24] Sterling Thomas,et al. A survey of current software for network analysis in molecular biology , 2010, Human Genomics.
[25] M. Jensen,et al. Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction , 2010, British Journal of Cancer.
[26] K. Yamaguchi,et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] H. Karaki. Guidelines for Proper Conduct of Animal Experiments by the Science Council of Japan , 2008 .
[28] R. Ueda,et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] John D. Storey,et al. A network-based analysis of systemic inflammation in humans , 2005, Nature.
[30] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[31] P. Angel,et al. AP-1 subunits: quarrel and harmony among siblings , 2004, Journal of Cell Science.
[32] J. Jauniaux,et al. Interaction of retroviral Tax oncoproteins with tristetraprolin and regulation of tumor necrosis factor-alpha expression. , 2003, Journal of the National Cancer Institute.
[33] M. Daly,et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.
[34] M. Tomonaga,et al. A new G‐CSF‐supported combination chemotherapy, LSG15, for adult T‐cell leukaemia‐lymphoma: Japan Clinical Oncology Group Study 9303 , 2001, British journal of haematology.
[35] M. Tomonaga,et al. Constitutive activation of transcription factor AP-1 in primary adult T-cell leukemia cells. , 2000, Blood.
[36] S. Trejo,et al. The Tax Protein of Human T-cell Leukemia Virus Type 1 Mediates the Transactivation of the c-sis/Platelet-derived Growth Factor-B Promoter through Interactions with the Zinc Finger Transcription Factors Sp1 and NGFI-A/Egr-1* , 1997, The Journal of Biological Chemistry.
[37] N. Nomura,et al. HTLV-1 Tax induces expression of various immediate early serum responsive genes. , 1991, Oncogene.
[38] John D. Minna,et al. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma , 1980, Proceedings of the National Academy of Sciences.
[39] Brad T. Sherman,et al. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.
[40] G. Courtois,et al. Complementation cloning of NEMO, a component of the IkappaB kinase complex essential for NF-kappaB activation. , 1998, Cell.